Theriva Biologics, Inc. (TOVX) Operating income 2016–2025
Theriva Biologics, Inc. (TOVX) annual operating income history from SEC filings — each fiscal year as reported.
-$24.1MFY2025 · since FY2016: -$39.3M → -$24.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$24.1M | +8.7% |
| FY2024 | -$26.3M | -22.9% |
| FY2023 | -$21.4M | +0.7% |
| FY2022 | -$21.6M | -51.2% |
| FY2021 | -$14.3M | -40.5% |
| FY2020 | -$10.2M | +35.1% |
| FY2019 | -$15.7M | +10.9% |
| FY2018 | -$17.6M | +33.1% |
| FY2017 | -$26.3M | +33.1% |
| FY2016 | -$39.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TOVX financial trends
TOVX RevenueTOVX Net incomeTOVX Net marginTOVX Gross profitTOVX Gross marginTOVX Operating marginTOVX Operating cash flowTOVX Free cash flowTOVX Capital expendituresTOVX Return on equityTOVX Stock buybacksTOVX Dividends paidTOVX Total assetsTOVX Total liabilitiesTOVX Shareholders’ equityTOVX overview →